VCP ScannerFree US Stock Screener & Financial AnalysisFree US Stock Screener
ScreenerThemesMarketEarningsCompareWatchlistInsider
ENTAEnanta Pharmaceuticals, Inc.
$12.66$294M
Research
Overview
Valuation
ValuationTargetsPrice
Financials
RevenueEarningsP/ERatiosDividend
Ownership
Holders
Tools
Total ReturnDCA Calculator
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Verify deeply. Act with conviction.

Data updated daily

Product

  • Screener
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly stock ideas — free

Follow VCP Scanner on XFollow VCP Scanner on LinkedIn
© 2026 VCP Scanner
AboutPrivacyTerms
Not financial advice. Do your own research.
ScreenerNewsCompareWatchlist
HomeStocksENTAEarnings History

ENTA logoEnanta Pharmaceuticals, Inc. (ENTA) Earnings History

Net Loss

15 years of earnings data (2011–2025) · Currently unprofitable on a TTM basis

TTM Net Income
-$62M
● Net Loss
TTM EPS (Diluted)
$-2.15
Per share, diluted
YoY EPS Growth
+29.9%
Excellent
Net Margin
-125.4%
After-tax profitability
EPS Growth Rate (CAGR)
1YN/A
3YN/A
5YN/A
10YN/A
Operating Margin-130.7%
Gross Margin93.0%
Return on Equity-84.6%
Return on Assets-24.9%
Record Annual Net Income$79MFY2015
Record Quarterly EPS$2.61Q3 2014
Consecutive Profitable Years0years
Q2 2026
Net Income-$13M
EPS (Diluted)$-0.45
YoY Growth+29.9%Excellent
QoQ Growth-9.7%Slow

Loading earnings history...

Enanta Pharmaceuticals, Inc. (ENTA) Earnings Overview

As of June 21, 2026, Enanta Pharmaceuticals, Inc. (ENTA) reported trailing twelve-month net income of -$62M, reflecting +29.9% year-over-year growth. The company earned $-2.15 per diluted share over the past four quarters, with a net profit margin of -125.4%.

Looking at the long-term picture, ENTA's historical earnings data spans multiple years. The company achieved its highest annual net income of $79M in fiscal 2015.

Enanta Pharmaceuticals, Inc. is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →

Compared to peers including ACHV (-$52M net income), AGIO (-$423M net income, -764.0% margin), ARQT (-$2M net income, -4.3% margin), ENTA has comparable earnings metrics. Compare ENTA vs ACHV →

ENTA Earnings vs Peers

Earnings metrics vs comparable public companies

CompanyTTM Net IncomeTTM EPSNet MarginROEYoY GrowthCompare
ENTA logoENTACurrent
-$62M$-2.15-125.4%-84.6%+29.9%—
ACHV logoACHV
-$52M$-0.97--257.7%-0.8%
AGIO logoAGIO
-$423M$-7.19-764.0%-30.2%-161.2%
ARQT logoARQT
-$2M$-0.02-4.3%-9.3%+88.8%
PRTA logoPRTA
-$151M$-2.79-2520.6%-63.6%-99.6%
FOLD logoFOLD
-$27M$-0.09-4.3%-11.6%+51.2%
Best in group
Lowest in group

ENTA Historical Earnings Data (2011–2025)

15 years
Fiscal Year Net Income YoY % Operating Income EPS (Diluted) Net Margin Op. Margin
2025-$82M+29.4%-$85M$-3.84-125.4%-130.7%
2024-$116M+13.3%-$122M$-5.48-171.6%-179.9%
2023-$134M-9.9%-$137M$-6.38-169.0%-173.2%
2022-$122M-54.1%-$124M$-5.91-141.3%-143.7%
2021-$79M-118.4%-$110M$-3.92-81.4%-112.9%
2020-$36M-178.0%-$42M$-1.81-29.5%-34.0%
2019$46M-35.5%$37M$2.2122.6%17.9%
2018$72M+306.3%$88M$3.4834.8%42.7%
2017$18M-18.3%$25M$0.9117.2%23.9%
2016$22M-72.6%$31M$1.1324.5%34.9%
2015$79M+129.4%$124M$4.0949.1%77.2%
2014$34M+257.7%$19M$1.8072.1%39.8%
2013$10M-55.0%$9M$-0.6730.0%28.2%
2012$21M-8.2%$21M$8.1151.3%51.0%
2011$23M-$25M$8.8455.7%60.4%

Download Data

Export ENTA earnings history in CSV or JSON format

Free sign-in required to download data

Consensus-Based Analysis Tools

Intrinsic Valuation

DCF models, multiple analysis, and analyst estimates.

Check Valuation

Historical Returns

15+ years return with dividends reinvested.

Calculate

DCA Calculator

See how regular investing compounds over time.

Run Numbers

Peer Comparison

Compare growth, multiples, and margins vs sector.

Compare

ENTA — Frequently Asked Questions

Quick answers to the most common questions about buying ENTA stock.

What is ENTA earnings per share (EPS)?

ENTA trailing twelve-month (TTM) diluted EPS is $-2.15, reflecting +29.9% year-over-year growth. The 5-year EPS CAGR is N/A. Complete EPS history from 2011 to 2025 is available in the table on this page.

What is Enanta Pharmaceuticals, Inc.'s net income?

Enanta Pharmaceuticals, Inc. (ENTA) trailing twelve-month net income is $-62M as of 2025. Earnings grew +29.9% year-over-year.

Is ENTA profitable?

ENTA is not currently profitable on a TTM basis, reporting a net loss of $-62M. Net margin is -125.4%. Investors should monitor for a return to profitability.

What is ENTA's earnings growth rate?

ENTA compound annual EPS growth rates (CAGR): 1-Year: N/A, 3-Year: N/A, 5-Year: N/A, 10-Year: N/A. These figures measure the annualised rate of diluted EPS growth over each period, based on data from 2011 to 2025.

What are ENTA's profit margins?

Enanta Pharmaceuticals, Inc. net profit margin is -125.4%, operating margin is -130.7%, and gross margin is +93.0%. Below-average margins reflect competitive or cost pressures. Return on Equity is -84.6%.

Is ENTA growing earnings?

Yes, ENTA earnings are accelerating — EPS growth of +29.9% exceeds the 5-year CAGR of N/A. TTM net income reached $-62M. Earnings momentum is strengthening.

What was ENTA's best earnings year?

Enanta Pharmaceuticals, Inc.'s highest annual net income on record is $79M, achieved in fiscal year 2015. Earnings history on this page spans 2011 to 2025 and includes all annual and quarterly figures.

What were ENTA's earnings last quarter?

ENTA's most recent reported quarter was Q2 2026. Net income was $-13M with diluted EPS of $-0.45. For a full breakdown of all quarters, see the quarterly earnings table on this page.

ENTA Earnings Over Time (2011–2025)

Net income & EPS — annual and quarterly view